Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 29,372 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke. DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Friday, November 18, 2022
Boswellic acids as promising agents for the management of brain diseases
Earlier research from 2019 had this line: patients who were allocated to BA group had a
significant recovery in neurological function during the 1-month
follow-up.
So why the hell aren't you writing a protocol on this instead of this waste of time on a systematic review? Your mentors and senior researchers incompetently did not know about it?
Boswellic acid (BA)s are pentacyclic triterpenic acids present in gum resin of Boswellia species (such as B. serrata and B. carterii).
They possess a variety of pharmacological effects such as
anti-inflammatory, anti-oxidant, and anti-excitotoxic effects. These
properties may have potential therapeutic implication in neurological
disorders. Notably, the BAs-induced neuroprotection is proposed to be
associated with the ability to reduce neurotoxic aggregates, decrease
oxidative stress, and improve cognitive dysfunction. Recently, BAs have
been suggested as potential agents for the treatment of brain tumors due
to their potential to attenuate cell proliferation, migration,
metastasis, angiogenesis, and promote apoptosis during both in vitro and in vivo
studies. The present review aims to address these studies and
highlights the possible underlying mechanisms of the observed effects.
Besides, novel formulations and improving pharmacokinetic properties may
enhance the therapeutic efficacy of BAs.
No comments:
Post a Comment